Healthcare Industry News: Transdermal
News Release - June 29, 2006
Transport Pharmaceuticals Names Sean Moran Chief Financial OfficerFRAMINGHAM, Mass., and PHILADELPHIA, Pa., June 29 (HSMN NewsFeed) -- Transport Pharmaceuticals, Inc., a leader in the convergence of medical devices and therapeutics for the topical treatment of dermatological conditions, today announced the appointment of Sean Moran as Chief Financial Officer.
Dennis Goldberg, President and Chief Operating Officer commented on the appointment, "We are thrilled to have attracted a CFO of Sean's stature. He brings a wealth of expertise in financial management, corporate finance, operations and public company experience to Transport. His background in both therapeutics and medical devices will be an added benefit. Sean will be an instrumental member of Transport's senior management team."
With more than twenty years of financial management experience, Mr. Moran, 48, joins Transport after four years as CFO at Sontra Medical Corporation, a publicly traded Transdermal drug delivery and diagnostic company. Previously, he was CFO of SatCon Technology Corporation, a publicly traded developer of energy management products. Prior to SatCon, Mr. Moran was CFO of Anika Therapeutics, a publicly traded biopharmaceutical company. Mr. Moran is a Certified Public Accountant and holds a Bachelor of Science in Business Administration. He earned his Master of Business Administration from Babson College.
About Transport Pharmaceuticals, Inc.
Privately held, Transport Pharmaceuticals, Inc. is a leader in the convergence of medical devices and therapeutics for the topical treatment of dermatologic conditions with an initial focus on infectious diseases. The Company is developing the combination of proprietary electrokinetic devices and Transdermal drug formulations for multiple dermatological diseases. Transport's lead product is a drug/device combination currently in clinical development to treat herpes labialis, or cold sores. The combination product delivers acyclovir, an approved cold sore treatment, directly to impacted skin areas, at concentrations considerably higher than conventional topical formulations. Transport plans to further leverage its convergent drug/device technology platform in additional dermatological diseases such as onychomycosis and psoriasis.
To date, the Company has raised USD $33.5 million. Current venture investors include Quaker BioVentures, The Carlyle Group, The Hillman Company and EGS Healthcare. For more information, please visit http://www.transportpharma.com.
Source: Transport Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.